Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer

Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic

MORRISTOWN, N.J., Dec. 1, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the appointment of Margaret Dugan, MD, as Chief Medical Officer (CMO). Dr. Dugan brings more than 30 years of global oncology drug development experience, with extensive expertise in early-stage clinical development and regulatory strategy.

Read more at prnewswire.com